Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy.
The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 17, 24 | -0.88 Decreased by -31.34% | -0.14 Decreased by -528.57% |
| Feb 21, 24 | -0.06 Decreased by -500.00% | -0.08 Increased by +25.00% |
| Nov 7, 23 | -0.58 Decreased by -1.83 K% | -0.31 Decreased by -87.10% |
| Aug 17, 23 | -0.32 Increased by +56.76% | -0.17 Decreased by -88.24% |
| May 16, 23 | -0.67 Decreased by -27.42% | -0.38 Decreased by -76.32% |
| Feb 23, 23 | -0.01 Increased by +98.95% | -0.57 Increased by +98.25% |
| Nov 14, 22 | -0.03 Decreased by -160.00% | -0.92 Increased by +96.74% |
| Aug 18, 22 | -0.74 Increased by +2.63% | -1.00 Increased by +26.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 451.56 M Increased by +5.25% | -18.37 M Decreased by -398.99% | Decreased by -4.07% Decreased by -374.11% |
| Dec 31, 23 | 451.56 M Increased by +5.25% | -18.37 M Decreased by -398.99% | Decreased by -4.07% Decreased by -374.11% |
| Sep 30, 23 | 294.59 M Increased by +13.28% | -168.36 M Decreased by -1.75 K% | Decreased by -57.15% Decreased by -1.53 K% |
| Jun 30, 23 | 269.38 M Increased by +320.60% | -91.93 M Increased by +52.22% | Decreased by -34.13% Increased by +88.64% |
| Mar 31, 23 | 429.04 M Increased by +1.28 K% | -3.68 M Increased by +98.32% | Decreased by -0.86% Increased by +99.88% |
| Dec 31, 22 | 429.04 M Increased by +1.28 K% | -3.68 M Increased by +98.32% | Decreased by -0.86% Increased by +99.88% |
| Sep 30, 22 | 260.06 M Increased by +31.23% | -9.11 M Decreased by -241.26% | Decreased by -3.50% Decreased by -207.64% |
| Jun 30, 22 | 64.05 M Increased by +N/A% | -192.43 M Decreased by -20.39% | Decreased by -300.45% Decreased by N/A% |